Glaxis Capital Management LLC Sells 6,500 Shares of Novo Nordisk A/S (NYSE:NVO)

Glaxis Capital Management LLC lowered its stake in shares of Novo Nordisk A/S (NYSE:NVO - Free Report) by 65.0% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 3,500 shares of the company's stock after selling 6,500 shares during the period. Novo Nordisk A/S accounts for 1.6% of Glaxis Capital Management LLC's holdings, making the stock its 20th biggest position. Glaxis Capital Management LLC's holdings in Novo Nordisk A/S were worth $417,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also added to or reduced their stakes in the business. Advisor OS LLC boosted its position in Novo Nordisk A/S by 0.6% in the second quarter. Advisor OS LLC now owns 13,972 shares of the company's stock worth $1,994,000 after purchasing an additional 82 shares during the last quarter. Cascade Financial Partners LLC raised its stake in Novo Nordisk A/S by 2.3% during the second quarter. Cascade Financial Partners LLC now owns 3,801 shares of the company's stock valued at $543,000 after buying an additional 84 shares during the last quarter. Novare Capital Management LLC grew its holdings in shares of Novo Nordisk A/S by 3.2% in the third quarter. Novare Capital Management LLC now owns 2,727 shares of the company's stock worth $325,000 after acquiring an additional 85 shares during the period. AA Financial Advisors LLC lifted its position in shares of Novo Nordisk A/S by 3.2% in the second quarter. AA Financial Advisors LLC now owns 2,805 shares of the company's stock valued at $400,000 after acquiring an additional 86 shares in the last quarter. Finally, Steel Grove Capital Advisors LLC lifted its position in shares of Novo Nordisk A/S by 2.3% in the second quarter. Steel Grove Capital Advisors LLC now owns 3,790 shares of the company's stock worth $541,000 after buying an additional 86 shares in the last quarter. Institutional investors own 11.54% of the company's stock.

Novo Nordisk A/S Price Performance

NVO traded up $2.67 during midday trading on Wednesday, hitting $105.30. The company had a trading volume of 7,517,325 shares, compared to its average volume of 4,496,117. The company has a market capitalization of $472.51 billion, a PE ratio of 33.22, a P/E/G ratio of 1.31 and a beta of 0.42. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.75 and a current ratio of 0.94. Novo Nordisk A/S has a twelve month low of $94.73 and a twelve month high of $148.15. The firm's 50-day simple moving average is $117.40 and its 200-day simple moving average is $129.27.

Analyst Upgrades and Downgrades

NVO has been the topic of a number of analyst reports. Cantor Fitzgerald restated an "overweight" rating and set a $160.00 target price on shares of Novo Nordisk A/S in a research report on Wednesday, November 6th. BMO Capital Markets reduced their target price on shares of Novo Nordisk A/S from $160.00 to $156.00 and set an "outperform" rating for the company in a report on Thursday, October 17th. Finally, StockNews.com upgraded shares of Novo Nordisk A/S from a "buy" rating to a "strong-buy" rating in a research report on Friday, November 1st. One research analyst has rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of "Buy" and an average price target of $144.50.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.